All In Biotech

Drug Trial Radar · NCT06500299

Evaluate the Safety and Efficacy of HDM1002 Tablets in Overweight and Obese Adults

A Multicenter, Randomized, Double-blind, Placebo-controlled Phase II Clinical Trial to Evaluate the Safety and Efficacy of HDM1002 Tablets in Overweight and Obese Adults

Last checked: Nov 19, 2026Latest source record: Jul 15, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingRandomized with 180 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

180

Planned (sponsor's estimate)

Start

Jul 15, 2024

Primary completion

Oct 30, 2024

Study completion Nov 30, 2024

Sponsor

Sponsor type
Industry
First posted
Jul 15, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

It is a multicenter, randomized, double-blind, placebo-controlled phase II clinical trial to evaluate the safety and efficacy of HDM1002 tablets in overweight and obese adults.

Conditions

  • Overweight and Obesity

Interventions

  • HDM1002 100 mg QDDrug

    HDM1002 tablets 100mg daily, 12weeks

  • HDM1002 200 mg QD 12weeksDrug

    HDM1002 tablets 200mg daily, 12weeks

  • HDM1002 400 mg QD 12weeksDrug

    HDM1002 tablets 400mg daily, 12weeks

  • PlaceboDrug

    Matching placebo will be provided

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage Change From Baseline in Body Weight at Week 12Time frame: Baseline, Week 12

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.